Washington, DC 20006-5349
HELPLINE
MESOTHELIOMA NEWS
Scroll to find news of interest to you, or search by category. The Mesothelioma Applied Research Foundation covers mesothelioma news for patients and their families. Our write-ups are heavily reliant on peer-reviewed medical research studies with input from mesothelioma experts from around the world but are also accessible to non-medical readers.
A new approach of anti-PD1 immunotherapy (atezolizumab) combined with bevacizumab (an agent that blocks the growth of new blood vessels therefore limiting the supply of
Join us next Tuesday, June 9 at 2:00 PM ET for a Meet the Mesothelioma Experts (MTME) interview with Dr. Zachary Horne on Facebook Live.
Anna Nowak, MD, PhD, speaks about immunotherapy and combination of immunotherapy and chemotherapy for mesothelioma patients. She also discusses COVID-19’s effects on mesothelioma in treatment in Australia.
A phase 2 immunotherapy clinical trial combining durvalumab, an immunotherapy drug, with standard treatment of Alimta (pemetrexed)/cisplatin has shown promising overall survival results. The study enrolled 55 patients and
Buerkley Rose, MSN, RN, discusses how the University of Chicago’s mesothelioma program has adapted during the COVID-19 pandemic: Clinical Trials: Paused. Telemedicine, including psycho-oncology services: Available. Surgery:
Dr. R. Taylor Ripley discusses his research interests, diet and cancer, as well as seeking care and the mesothelioma program at Baylor College of Medicine during COVID-19: Telemedicine: Available
In 2016, the Mesothelioma Applied Research Foundation funded a grant to Antonio Giordano, MD, PhD, director and founder of the Sbarro Health Research Organization at Temple University, to investigate how silencing
Dr. Marjorie G. Zauderer reviews the changes at Memorial Sloan Kettering Cancer Center, located in NYC, during COVID-19: Telemedicine: Available + Dr. Zauderer provides tips for